top of page
Contact Us

Understanding the Content of Premarket Submissions for Device Software Functions


In the rapidly evolving field of medical devices, software plays a critical role in enhancing their functionality and performance. As the demand for innovative healthcare solutions continues to rise, regulatory bodies such as the U.S. Food and Drug Administration (FDA) have established guidelines to ensure the safety and effectiveness of medical device software. In this blog post, we will explore the content of premarket submissions for device software functions, shedding light on the essential aspects Companies must consider when seeking regulatory clearance.

This framework is generalized, and specific submissions are expected to vary.


The Importance of Premarket Submissions


Premarket submissions enable medical device companies to demonstrate compliance with regulatory requirements and obtain necessary approvals before marketing their products. For device software functions, these submissions are key to ensuring patient safety, product quality, and overall device performance.


Regulatory Landscape for Device Software


Understanding the regulatory landscape is crucial for manufacturers developing medical device software. In the United States, the FDA's Center for Devices and Radiological Health (CDRH) oversees the regulation of medical devices, including software. Premarket submissions for device software functions are subject to the FDA's software premarket notification process.


Key Components of Premarket Submissions


Device Description: The submission should comprehensively describe the software's intended use, its interaction with the medical device, and any other relevant information about the device software system.


Risk Analysis: Companies must conduct a thorough risk analysis, identifying and assessing potential hazards associated with the software. This includes considering potential use errors, cybersecurity risks, and adverse effects on patient safety or device performance.


Software Development Process: Details about the software development process, including methodologies, design controls, and validation and verification procedures, should be included in the submission. This demonstrates that the software has been developed and tested systematically and controlled.


Verification and Validation: Documentation should outline the verification and validation activities performed to ensure that the software functions as intended, meet user requirements, and performs reliably under various conditions.


Usability and Human Factors Engineering: Information regarding usability and human factors engineering efforts can be important. Companies may be required to conduct studies or evaluations to assess the software's user interface, user interactions, and potential use errors.


Clinical Data: Depending on the device's risk classification, companies may need to provide clinical data demonstrating the software's safety and effectiveness. This may include clinical investigations, non-clinical testing, or published literature supporting the device's intended use.


Post-Market Surveillance and Reporting


Companies may need to address post-market surveillance plans and procedures for monitoring the software's performance once it reaches the market. This includes mechanisms for capturing and reporting adverse events, analyzing real-world data, and implementing necessary corrective actions.


We are here to help.


Developing and submitting a premarket application for device software functions requires careful attention to regulatory requirements and thorough documentation.

Biomedical Statistical Consulting routinely designs and advises on clinical trial efforts addressing these requirements. Contact info@biomedstat.com for more information.

The guide can be found on the FDA page.

Beyond The Page

Expertise in Every Niche.

Congratulations to Brendan Keenan and Greg Maislin for their recent publication on Propensity Score designs!

In the article, the authors propose that Propensity Score designs are the optimal approach to address the impact of continuous positive airway pressure (CPAP) on cardiovascular events.

Congratulations to BSC®’s David Maislin, Alex Breno, and our friends at 3Spine on their recent publication!

The article lays out the protocol for the pivotal IDE trial behind 3Spine's MOTUS® lumbar Total Joint Replacement, the first device built to restore both disc and facet joint function without sacrificing motion. 

Congratulations to David Maislin and Brendan Keenan on their article in collaboration with UPenn!

This article cover the effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling in Non-Obese and Obese Adults.

WHAT CLIENTS SAY

“They listen the first time. I’ve never had to go back and respell out what I needed." 


”They work to understand the problem and leverage the information that is already there.”

Former FDA Regulator

WHAT CLIENTS SAY

"Battle ground tested."


"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”

Vice President, Clinical Operations

WHAT CLIENTS SAY

"Get stuff done when you have to do something no one else has done before."


"They aren’t afraid to tackle difficult scenarios in compressed timelines."

CEO, Medical Device Company

BSC® Differentiator

What Sets us Apart

Submission Grade Experience

Regulatory-first biostatistics

Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.

Direct communication, faster turn around

Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.

Versatile Solutions

Engage us for a focused analysis or a full submission, We size the work to the problem.

Proven FDA Experience

Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.

bottom of page